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Current therapeutic procedures for emergency management 
of ischemic heart disease may be ineffective without a prompt 
reestablishment of regional oxygenated blood supply. De•
livery of pharmacologic agents to regional jeopardized myo•
cardium may also be seriously hindered because of an ob•
structed coronary artery circulation. In such circumstances, 
emergency techniques developed in our laboratory employ•
ing the coronary venous channels can provide a temporary, 
safe alternate route for the emergency retrograde supply of 
oxygenated blood or pharmacologic agents for support of 
jeopardized ischemic myocardium. 
A coronary sinus intervention in the form of surgical 
retroperfusion was extensively investigated by Claude Beck 
and his contemporaries in the 1940s, employing a permanent 
aorta to coronary sinus anastomosis, coupled with partial 
coronary sinus obstruction. The Beck procedure was en•
thusiastically applied in approximately 200 patients with 
ischemic heart disease (1,2) but was abandoned because of 
late complications that resulted from myocardial edema, 
vascular damage and fibrosis caused by impairment of the 
coronary venous drainage (3). In the last 13 years, we have 
overcome these dreaded complications with a synchronous 
retroperfusion system that provides time sharing of the coro•
nary veins, thus permitting retrograde propulsion of the 
patient's own arterial blood into jeopardized ischemic myo•
cardium through the coronary veins while maintaining re•
gional venous drainage (4-7). 
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Synchronized Diastolic Retroperfusion 
Synchronized diastolic retroperfusion of the regional 
coronary veins was developed as an effective and clinically 
applicable temporary nutritional support of jeopardized acutely 
ischemic myocardium. This technique shunts the patient's 
own arterial blood from the femoral or brachial artery into 
an electrocardiographically triggered synchronized pump that 
then propels the oxygenated blood during diastole through 
an autoinflatable balloon-tipped catheter unidirectionally 
through regional coronary veins that subserve the ischemic 
myocardium (Fig. 1 and 2). Sudden collapse of the balloon 
during systole facilitates normal physiologic coronary ve•
nous drainage to prevent the complications of excessive 
coronary sinus pressure (7). Experimental investigations of 
synchronized retroperfusion have been performed rapidly 
and safely in hundreds of closed chest dogs. 
Role in myocardial ischemia and infarction. Studies 
with acute experimental coronary occlusion in animals re•
vealed that synchronized retroperfusion significantly im•
proves cardiac contractile and metabolic function within 
minutes (4-8). These improvements have been shown to 
persist during 5Y2 hours of continuous regional retroper•
fusion during maintained coronary artery occlusion. When 
normothermic synchronized retroperfusion was initiated in 
the early stage of acute ischemia while the myocardium was 
still viable, that is, within 30 to 180 minutes after onset of 
occlusion, significant infarct size reduction could be dem•
onstrated. These benefits have been corroborated in several 
laboratories (4-9). Furthermore, when the arterial blood was 
cooled moderately while it was being retroperfused into the 
regional coronary veins, there was additional improvement 
in cardiac function and myocardial salvage (10-12). None 
of the severe "no reflow" derangements frequently en•
countered with sudden reperfusion were noted when the 
myocardial region at high risk was pretreated with retro•
perfusion (11). This suggests that synchronized retroper•
fusion could become a useful intervention for protection and 
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Figure 1. Retroperfusion (SRP) catheter in the great cardiac vein. 
The arrow in the center indicates the proximal site of occlusion 
of the left anterior descending coronary artery in the experimental 
model. A.I. = anterior interventricular vein; RA = right atrium. 
treatment of jeopardized acutely ischemic myocardium until 
definitive revascularization measures such as coronary an•
gioplasty, arterial bypass or thrombolysis can be imple•
mented for reestablishment of adequate anterograde perfusion. 
Retroinfusion 
We also developed and applied simple retroinfusion sys•
tems for direct retrograde instillation of pharmacologic agents 
such as prostaglandin E" streptokinase and procainamide 
into the coronary veins (13-15). Retroinfusion of a phar•
macologic agent into the regional coronary vein accompa•
nied by temporary coronary sinus occlusion to improve myo•
cardial absorption of the drug promotes selective drug delivery. 
As a safety feature, retroinfusion should be performed with 
coronary venous pressure monitoring to warn of excessive 
coronary venous pressures, to permit immediate balloon 
deflation and interruption of retroinfusion. 
Experimental investigations of retroinfusion. Our 
studies have already suggested significant potential benefits. 
1. Prostaglandin E 1 administered into the coronary veins 
by direct retroinfusion or retroperfusion led to improvement 
in jeopardized myocardial contractile function and promoted 
infarct salvage even in the most profoundly ischemic region 
(13). 
2. Arrhythmias: In this issue, Karagueuzian et a1. (15) 
have demonstrated that arrhythmias, refractory even to highly 
toxic doses of systemically administered procainamide, may 
be promptly and safely treated with relatively low doses of 
the agent administered through the regional coronary veins. 
The concentration of procainamide was many times greater 
in the jeopardized retroperfused tissue than in remote normal 
myocardium (15). 
Otsu et a1. (16) have also shown that lidocaine retroin•
fusion through the coronary sinus is more effective than 
systemic administration during acute coronary occlusion. 
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3. Thrombolysis: Streptokinase administered by way of 
the coronary veins, either by sequential bolus infusion or 
continuous retroinfusion or retroperfusion of the coronary 
veins provided, with minimal dosage, rapid lysis of an ex•
perimental intravascular coronary artery thrombus (14). Ini•
tial lysis of the thrombus was demonstrated to be signifi•
cantly faster with coronary venous as compared with systemic 
intravenous administration. This method, using low doses 
of streptokinase, might reduce the incidence of hemorrhagic 
complications encountered with systemic streptokinase 
treatment which requires doses in excess of 1 million units. 
Moreover, when the thrombolytic agents are adminis•
tered in conjunction with arterial blood retroperfusion, there 
is immediate protection of the jeopardized ischemic area 
while awaiting thrombolysis. Such support by synchronized 
retroperfusion in the experimental animal has been shown 
to reduce the prolonged derangements of ischemia experi•
enced in a considerable number of patients who have ob•
tained potentially satisfactory reperfusion but have exhibited 
delayed or no improvement in cardiac function (2-4). 
4. Administration of cardioplegia through the coronary 
sinus has already been applied during coronary bypass graft 
surgery and aortic valve replacement. Because the coronary 
veins, in contrast with coronary arteries, are usually free of 
Figure 2. Operation of the retroperfusion autoinflatable balloon 
catheter. During ventricular diastole (upper panel) the balloon is 
inflated to propel arterial blood retrograde toward the ischemic 
zone. During onset of systole (lower panel), retroinfusion stops, 
the balloon collapses promptly and regional coronary veins drain 
naturally into the coronary sinus. CS = coronary sinus; GCV = 
great cardiac vein. 
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atherosclerotic obstructions, the alternate coronary venous 
delivery appears to provide a more uniform distribution of 
hypothermia and cardioplegia than can be achieved with 
anterograde cardioplegic administration (17,18). 
Air embolism: A recent report (19) indicates that the 
dreaded complication of massive air embolization of the 
coronary arteries during surgery can be successfully treated 
by coronary venous retroinfusion of cardioplegic agents. 
Potential Clinical Application of Coronary 
Venous Delivery 
Experimental studies indicate that the primary benefits 
of coronary venous synchronized retroperfusion during acute 
myocardial ischemia are: 1) a prompt and significant res•
toration of regional myocardial perfusion, particularly in the 
severely jeopardized subendocardial layer (20), 2) a rapid 
and significant restoration of ischemic zone metabolism and 
contractile function, along with improved global ventricular 
function, and 3) preservation of myocardial viability and 
reduction in infarct size with and without reperfusion. Re•
cent investigations (20) of detailed mechanisms suggest that 
the benefits of synchronized retroperfusion may be derived 
not only from retrogradely enhanced regional myocardial 
perfusion and oxygenation, but also from enhanced washout 
of toxic metabolites from the acutely ischemic myocardium. 
Safety. Although coronary sinus catheterization has been 
shown to be safe when performed for diagnostic purposes, 
coronary venous retroperfusion is not without risk. Trauma 
to the coronary veins, a potential complication, was noted 
during our earliest animal trials. Detailed pathologic studies 
of the autopsied dog hearts revealed that the damage was 
caused by a sharp catheter tip that tore a hole in the vessel. 
Modification of the catheter design has solved this problem, 
and in approximately 400 recent animal studies a soft tipped 
catheter has not caused any damage to the coronary venous 
system. Although physiologic coronary venous drainage is 
maintained with phased retroperfusion, elevations in coro•
nary sinus pressure, which might occur in the setting of 
excessive inflation or inadequate balloon deflation, can cause 
coronary venous hypertension and result in myocardial edema 
and hemorrhage. Hence, pressure monitoring should be in•
corporated in the design of retroperfusion and retroinfusion 
catheter and pumping systems to avoid this complication. 
Coronary sinus retroperfusion requires fluoroscopic guid•
ance for catheter placement. Although this requires some 
expertise, there is evidence that coronary sinus catheteriza•
tion can be achieved safely in minutes and should not present 
significant limitation to human application. 
Conclusions 
Experimental data suggest that the coronary veins indeed 
provide the potential for a prompt, effective alternate chan•
nel for delivery of oxygenated blood as well as pharma-
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cologic agents such as antiarrhythmic, thrombolytic and 
cardioprotective drugs, either by synchronized retroperfu•
sion or simple, nonphased retroinfusion to regionally isch•
emic myocardium. Improved myocardial viability can be 
expected promptly, not only in the setting of evolving acute 
myocardial infarction, but also during interventions such as 
percutaneous transluminal coronary angioplasty, which in•
volves the temporary interruption of anterograde blood flow 
and is associated with acute coronary occlusion in a small 
but significant proportion of patients. Synchronized retro•
perfusion may also provide a useful support in the future 
for performance of coronary angioscopy or laser angioplasty. 
If the success of coronary venous intervention is corrob•
orated in humans, this alternate channel approach should 
provide an important new therapeutic modality. Initial clin•
ical studies suggest synchronized retroperfusion will support 
the jeopardized myocardium during unstable angina (Gore 
J, personal communication, 1985) and coronary angioplasty 
(21). Ventricular tachycardia has also been successfully treated 
by coronary venous retroinfusion of procainamide (Berland 
J, personal communication, 1985). 
These results are encouraging. However, large scale clin•
ical trials are needed to confirm these preliminary data. 
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